A Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Dose-exploration Phase II Clinical Trial to Evaluate the Efficacy and Safety of NH102 in the Treatment of Depression
Latest Information Update: 28 Feb 2025
At a glance
- Drugs NH 102 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Jiangsu Nhwa Pharmaceutical
Most Recent Events
- 28 Feb 2025 New trial record